경피 모니터 시장 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the transcutaneous monitors market size was valued at USD 278.39 million in 2025 and estimated to grow from USD 295.84 million in 2026 to reach USD 400.97 million by 2031, at a CAGR of 6.27% during the forecast period (2026-2031).

This report is Segmented by Application (Wound Healing, Blood Gas Monitoring, and More), End User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Others), Parameter Monitored (Transcutaneous CO2, and More), Patient Age Group (Neonates, Pediatric, Adult, Geriatric), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Transcutaneous Monitors Market Trends and Insights

Growing Prevalence of Respiratory Diseases

Chronic obstructive pulmonary disease, sleep apnea, and post-viral respiratory complications are driving sustained demand for continuous non-invasive monitoring . Hospitals that introduced transcutaneous CO2 sensors in neonatal intensive care units reduced arterial blood draws by 25%, lowering infection risk and nursing time. Home-based sleep-diagnostic programs using smartwatch-linked oximetry algorithms achieved 89.4% sensitivity, illustrating the shift from clinic-centric testing to consumer-friendly screening . U.S. coverage determinations now deem transcutaneous systems medically necessary for restrictive thoracic disorders, broadening reimbursement and reinforcing their role in value-based care. Together, disease burden and policy alignment underpin a robust outlook for the transcutaneous monitors market.

Technological Miniaturization & Sensor Accuracy Gains

Luminescence, photoacoustic, and electronic-paramagnetic-resonance sensing have trimmed probe footprints while dispensing with heating membranes, clearing a path for round-the-clock wearables that rival arterial sampling accuracy. Non-contact epidermal flux monitors showcased by Nature reported clinically acceptable variance without direct skin coupling, extending use cases to fragile or burn patients. Masimo embedded ML-driven "Sleep Halo" analytics in consumer devices that log 70,000 daily health points, illustrating how software stickiness can lengthen hardware life cycles. The U.S. Food & Drug Administration recently cleared laser-based oximeters that correct melanin-related signal drop, signaling regulatory support for equity-minded accuracy upgrades. Such breakthroughs are expected to influence platform specifications for at least the next product generation.

Complex & Lengthy Regulatory Approvals

Europe's Medical Device Regulation widened classification scope to include stand-alone software, compelling manufacturers to run full clinical evaluations and post-market surveillance for transcutaneous systems. In the United States, Class II filings must show substantial equivalence with predicate devices and prove accuracy across diverse patient groups, often extending bench-to-bedside timelines. Although recent guidance permits limited data waivers, companies still prepare extensive technical dossiers for MDR and 510(k) submissions, straining smaller entrants and slowing iteration cycles. Divergent U.S.-EU evidence expectations oblige global firms to conduct parallel regulatory strategies, adding up-front compliance costs that can dampen innovation velocity.

Other drivers and restraints analyzed in the detailed report include:

1. Rise in Chronic Disorders Necessitating Continuous Monitoring
2. Demand Spike for Non-Invasive Neonatal & Critical-Care Monitoring
3. High Device & Sensor Replacement Cost

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Blood Gas Monitoring accounted for 41.02% of the transcutaneous monitors market size in 2025, reflecting decades of evidence that end-tidal and skin-based measurements reduce invasive sampling frequency in intensive-care suites. Integration with ventilator dashboards further cements its role in respiratory management. Wound Healing, though smaller, is advancing at a 6.95% CAGR. Hyperbaric clinics rely on transcutaneous oxygen (TcPO2) to triage limb-salvage candidates; values below 30 mmHg flag compromised microcirculation, prompting adjunctive therapy. As funding for diabetic-foot programs rises, TcPO2 is becoming a routine prognostic marker, placing this niche on a rapid ascent.

The convergence of expanded hyperbaric coverage and portable TcPO2 devices creates favorable conditions for outpatient wound centers. Societies now list TcPO2 as a pre-operative measure for peripheral arterial disease, embedding the test in vascular algorithms. Meanwhile, AI-enhanced capnography is spilling into sleep-diagnostic toolkits, foreshadowing new overlaps between pulmonary and wound-care domains. Consequently, the transcutaneous monitors market is widening its clinical footprint without cannibalizing incumbent segments.

Hospitals retained 67.12% of revenue in 2025 as critical-care units depend on round-the-clock physiology data. Yet Specialty Clinics are registering 7.03% CAGR because portable monitors now suit outpatient infusion centers and dialysis suites. Ambulatory Surgical Centers deploy single-use sensors to flag hypoventilation episodes during conscious sedation, mitigating post-op complications.

Philips' decision to move its Healthdot business into smartQare highlights an ecosystem pivot: open platforms that aggregate feeds from multiple vendors are edging out proprietary silos. The model improves staffing efficiency; one Dutch pilot demonstrated 47% less routine vitals collection when continuous wireless sensors fed directly into electronic medical records. Budget-minded clinics view such labor offsets as justification for capital outlay, fuelling demand beyond hospital campuses.

Complete Report Scope:

• By Application
  • Wound Healing
  • Blood Gas Monitoring
  • Respiratory Care
  • Sleep Diagnostics
  • Others
• By End User
  • Hospitals
  • Ambulatory Surgical Centers
  • Specialty Clinics
  • Others
• By Parameter Monitored
  • Transcutaneous CO2
  • Transcutaneous O2
  • Bilirubin
  • Combined Parameters
• By Patient Age Group
  • Neonates
  • Pediatric
  • Adult
  • Geriatric
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America continues to anchor the transcutaneous monitors market through robust reimbursement, integrated care networks, and a track record of technology uptake. Medicare covers multiple use cases, from ambulatory ECGs to continuous capnography, encouraging hospital procurement even during budget squeezes. BD's USD 4.2 billion purchase of Edwards Lifesciences' critical-care unit exemplifies scale-seeking consolidation aimed at building end-to-end monitoring ecosystems. Masimo's healthcare segment grew 10% in 2024 to USD 1,395 million, reflecting high replacement demand for advanced pulse oximeters and capnometers.

Asia-Pacific is the fastest-growing region at 7.05% CAGR, propelled by aging demographics, infrastructure upgrades, and harmonizing device rules. National reimbursement codes in Japan now bundle continuous oxygen monitoring into postoperative packages, while India's Ayushman Bharat scheme broadens public funding for critical-care instrumentation. Because many facilities leapfrog older wired technology, suppliers that offer mobile, cloud-linked monitors gain early-mover advantages. The region's dense innovation hubs also accelerate sensor R&D; several photoacoustic startups in South Korea and Singapore secured Series B funding for wearable capnographs in 2025.

Europe remains a sizeable but increasingly regulated arena. MDR enforcement lengthens submission lead-times, yet it also stabilizes quality expectations, which benefits manufacturers with strong clinical datasets. Roche's AI-assisted glucose sensor received CE Mark clearance in 2025 under the new rules, proving that evidence-rich dossiers can still move efficiently. Regional procurement patterns favor devices with proven workflow integrations; thus, platforms capable of merging with hospital EMRs see smoother tender wins. While currency volatility and varied national insurance models complicate pricing, the demand for neonatal and wound-healing monitors is rising as speciality clinics across Germany and France adopt hyperbaric programs.

1. SenTec
2. Radiometer
3. HUMARES GmbH
4. Perimed
5. Koninklijke Philips
6. Masimo
7. Dragerwerk
8. Siemens Healthineers
9. GE Healthcare
10. Medtronic
11. Kent Imaging
12. Perimed AB (PeriFlux)
13. Baxter International (O? Boot)
14. Natus Medical
15. Atom Medical Corp.
16. Nihon Kohden Corp.
17. Smith & Nephew (O? therapy patches)
18. Abbott Laboratories (Libre Sense)
19. AliveCor
20. iRhythm Technologies
21. Convatec
22. Solventum
23. Johnson & Johnson
24. Boston Scientific (TENS)

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Growing Prevalence of Respiratory Diseases
  • 4.2.2 Technological Miniaturization & Sensor Accuracy Gains
  • 4.2.3 Rise In Chronic Disorders Necessitating Continuous Monitoring
  • 4.2.4 Demand Spike for Non-Invasive Neonatal & Critical-Care Monitoring
  • 4.2.5 AI-Enabled Wearable Capnometry for Home & Sleep Diagnostics
  • 4.2.6 Hyperbaric-Medicine Expansion Driving Tcpo? Adoption in Wound Clinics
• 4.3 Market Restraints
  • 4.3.1 Complex & Lengthy Regulatory Approvals
  • 4.3.2 High Device & Sensor Replacement Cost
  • 4.3.3 Limited Clinician Training in TC Monitoring Workflows
  • 4.3.4 Skin-Tone Accuracy Bias Triggering Additional Validation Needs
• 4.4 Regulatory Landscape
• 4.5 Technological Outlook
• 4.6 Porters Five Forces Analysis
  • 4.6.1 Threat of New Entrants
  • 4.6.2 Bargaining Power of Buyers
  • 4.6.3 Bargaining Power of Suppliers
  • 4.6.4 Threat of Substitutes
  • 4.6.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Application
  • 5.1.1 Wound Healing
  • 5.1.2 Blood Gas Monitoring
  • 5.1.3 Respiratory Care
  • 5.1.4 Sleep Diagnostics
  • 5.1.5 Others
• 5.2 By End User
  • 5.2.1 Hospitals
  • 5.2.2 Ambulatory Surgical Centers
  • 5.2.3 Specialty Clinics
  • 5.2.4 Others
• 5.3 By Parameter Monitored
  • 5.3.1 Transcutaneous CO2
  • 5.3.2 Transcutaneous O2
  • 5.3.3 Bilirubin
  • 5.3.4 Combined Parameters
• 5.4 By Patient Age Group
  • 5.4.1 Neonates
  • 5.4.2 Pediatric
  • 5.4.3 Adult
  • 5.4.4 Geriatric
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 Sentec AG
  • 6.3.2 Radiometer
  • 6.3.3 HUMARES GmbH
  • 6.3.4 Perimed AB
  • 6.3.5 Koninklijke Philips N.V.
  • 6.3.6 Masimo Corporation
  • 6.3.7 Dragerwerk AG & Co. KGaA
  • 6.3.8 Siemens Healthineers
  • 6.3.9 GE HealthCare
  • 6.3.10 Medtronic plc
  • 6.3.11 Kent Imaging Inc.
  • 6.3.12 Perimed AB (PeriFlux)
  • 6.3.13 Baxter International (O? Boot)
  • 6.3.14 Natus Medical Inc.
  • 6.3.15 Atom Medical Corp.
  • 6.3.16 Nihon Kohden Corp.
  • 6.3.17 Smith & Nephew (O? therapy patches)
  • 6.3.18 Abbott Laboratories (Libre Sense)
  • 6.3.19 AliveCor Inc.
  • 6.3.20 iRhythm Technologies
  • 6.3.21 ConvaTec Group
  • 6.3.22 Solventum
  • 6.3.23 Johnson & Johnson (Ethicon)
  • 6.3.24 Boston Scientific (TENS)

7 Market Opportunities & Future Outlook

• 7.1 White-Space & Unmet-Need Assessment